Dangerous Abortion Pill Faces Congressional AXE

Ultrasound images and a bottle of misoprostol next to a pregnancy test

Senator Josh Hawley just introduced a bold bill to revoke FDA approval of the dangerous chemical abortion pill mifepristone, protecting women from its severe health risks after years of leftist regulatory failures.

Story Highlights

Hawley’s Safeguarding Women from Chemical Abortion Act targets mifepristone, used in 63% of 2023 abortions, as inherently dangerous with complication rates 22 times higher than FDA labels.
Bill bans nationwide distribution for abortions and empowers women harmed by the drug to sue manufacturers like Danco Laboratories.
Press conference featured real women testifying to life-threatening side effects like hemorrhaging and infections.
Escalates from Hawley’s 2025 safeguards push, directly challenging FDA overreach from Clinton era.

Bill Introduction and Key Provisions

Senator Josh Hawley (R-Mo.) introduced the Safeguarding Women from Chemical Abortion Act on March 11, 2026, at a Capitol press conference. The legislation revokes FDA approval of mifepristone, granted in 2000 under President Clinton. It classifies distribution of the drug for pregnancy termination as a federal violation. Women suffering harm gain a private right of action to sue manufacturers for damages. This targets companies profiting billions from what Hawley calls an inherently dangerous product prone to abuse. Pro-life leaders and affected women testified, highlighting real safety failures ignored by prior administrations.

Safety Concerns Backed by Data

Ethics and Public Policy Center research, cited by Hawley, analyzed 865,727 insurance claims from 2017-2023. It found mifepristone side effects occur at rates 22 times higher than FDA label indications. Over one in ten women experienced infection, hemorrhaging, or life-threatening events. This data underscores the bill’s focus on women’s health over abortion industry profits. Biden-era policies expanded mail-order access, enabling roughly 500 abortions daily without proper oversight. Conservatives see this as government-enabled endangerment of families and traditional values.

Historical Context and Escalation

Mifepristone dominates U.S. abortions, comprising 63% in 2023. The 2024 Supreme Court rejected a challenge on standing grounds, not safety merits. Post-Dobbs in 2022, states regained authority, yet federal inaction persisted. Hawley’s May 2025 bill sought FDA safeguards and lawsuits against telehealth providers. This 2026 measure goes further, asserting only Congress can reverse FDA errors. It reverses Biden expansions of telehealth and mail delivery, aligning with President Trump’s review of holdover policies while respecting states’ rights.

West Virginia’s Senate passed a state abortion pill ban on February 13, 2026, showing momentum. Such coordination bolsters family protections without national overreach.

Stakeholders and Legislative Path

Hawley leads with support from pro-life groups like Alliance for Hippocratic Medicine and Restoration of America Foundation. Danco Laboratories faces litigation risks. FDA Commissioner Marty Makary pledged a safety review, timeline unclear. Trump administration conducts its own assessment, pausing state suits, consistent with Trump’s veto stance on national bans. The bill lingers in early stages amid Republican Senate control. Passage faces hurdles from historical failures of federal restrictions since Dobbs. Conservatives urge action to shield women and unborn from chemical harms.

Potential Impacts and Conservative View

Enactment would end mifepristone’s role in most abortions, curbing telehealth/mail access and Biden leftovers. Manufacturers lose markets; providers halt prescriptions. Rural women, hit hardest by travel bans, gain protections from unmonitored drugs. Economically, it disrupts Big Pharma profits from unsafe products. Socially, it upholds life and family values against radical agendas. Politically, it tests Trump’s balancing of reviews with state efforts. True victory lies in prioritizing health data over abortion access rhetoric.